1,062
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular

Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States

, , , &
Pages 10-15 | Received 15 Sep 2023, Accepted 29 Nov 2023, Published online: 09 Dec 2023